Greenwich - Model GP2 - Nine Amino Acid Transmembrane Peptide of the HER2/Neu Protein
Following breast cancer surgery, a HER2/neu 3+ patient receives trastuzumab (Genentech/Roche’s Herceptin, a monoclonal antibody treatment that targets the HER2/neu protein) in the first year and then hopes that their breast cancer will not recur, with the odds of recurrence slowly decreasing over the first 5 years. Our immunotherapy, GP2, may be synergistic with Herceptin. GP2 is a nine amino acid transmembrane peptide of the HER2/neu protein. HER2/neu is a cell surface receptor protein that is expressed in 75% of breast cancer in addition to a variety of other common cancers. Following GP2 immunotherapy, CD8+ cytotoxic T lymphocytes (“CTLs”) recognize and destroy HER2/neu-expressing cancer cells. GP2 is administered in combination with GM-CSF, an FDA-approved immunoadjuvant, which stimulates the proliferation of antigen presenting cells.
-
Most popular related searches
Preclinical studies have shown that T cells sensit...
Preclinical studies have shown that T cells sensitized against the GP2 peptide demonstrate significant recognition of HER2/neu-expressing tumors. Both ovarian and breast cancer-specific CTLs recognize GP2, which is widely expressed in HER2/neu-expressing tumors and is capable of inducing tumor-specific CTL populations in vitro.
Four clinical trials were conducted that have explored GP2 immunotherapy to prevent the recurrence of breast cancer following surgery.
Customer reviews
No reviews were found for Greenwich - Model GP2 - Nine Amino Acid Transmembrane Peptide of the HER2/Neu Protein. Be the first to review!